Eli Lilly & Co

LLY

Equity

ISIN US5324571083 / Valor 947556

New York Stock Exchange, Inc (2024-09-17)

USD 906.18-1.88%

Eli Lilly & Co
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Eli Lilly & Co, headquartered in Indianapolis, is a global pharmaceutical company with a significant presence in the healthcare sector. Known for its research, development, and commercialization of pharmaceutical products, Eli Lilly focuses on a wide range of therapeutic areas including but not limited to oncology, diabetes, neurodegeneration, and immunology. The company has recently announced results from a pioneering study of lebrikizumab, a treatment specifically designed for individuals with skin of color suffering from moderate-to-severe atopic dermatitis, also known as eczema. This highlights Eli Lilly's commitment to addressing diverse medical needs and expanding its portfolio to include treatments tailored for specific demographic groups. The company's efforts in innovation and targeted research underscore its role in advancing medical treatments and improving patient outcomes across various disease states.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

In the first quarter of 2024, Eli Lilly & Co reported a significant revenue increase of 26% compared to the same period in the previous year, reaching $8.77 billion. This growth was primarily driven by strong sales of their products Mounjaro, Zepbound, Verzenio, and Jardiance.

Earnings Per Share Increase

Eli Lilly & Co's earnings per share (EPS) showed a robust increase in Q1 2024, with reported EPS rising by 66% to $2.48 and non-GAAP EPS increasing by 59% to $2.58. These figures include $0.10 of acquired IPR&D charges, reflecting significant profitability growth.

Net Income and Profitability

For Q1 2024, Eli Lilly & Co's net income surged by 67% to $2.24 billion on a reported basis. The increase in net income highlights the company's enhanced profitability and effective management of operational and financial activities.

Dividend and Outlook Enhancement

Eli Lilly & Co has raised its full-year revenue guidance for 2024 by $2 billion, indicating a positive outlook based on current performance trends. Additionally, the company increased its reported EPS guidance by $1.25, with new ranges of $13.05 to $13.55, and its non-GAAP EPS guidance by $1.30, with ranges of $13.50 to $14.00.

Operational Highlights and Future Prospects

During Q1 2024, Eli Lilly & Co made significant progress in its product pipeline, including positive results from Phase 3 trials and new drug submissions. The company's strategic investments in research and development are poised to bolster future growth, addressing global healthcare needs effectively.

Summarized from source with an LLMView Source

Key figures

57.4%1Y

294%3Y

715%5Y

Performance

30.2%1Y

28.4%3Y

31.6%5Y

Volatility